NCCN 2019 Hematologic Malignancies

Genetic Profiling and Personalized Medicine in Myelodysplastic Syndromes

Meg Barbor, MPH

December 2019, Vol 10, No 6 - NCCN 2019 Hematologic Malignancies

San Francisco, CA—Personalization of therapy in the treatment of patients with myelodysplastic syndrome (MDS) is focused primarily on risk classification of patients. Once clinical risk has been established, treatment considerations should be informed by features such as disease subtype, prognostic somatic mutations, chromosomal abnormalities, targetable somatic mutations, immunologic features, and patient factors, according to Rafael Bejar, MD, PhD, Assistant Professor of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA. [ Read More ]

Biosimilars Are Key Components of Oncology Today: Brush Up on the Basics

Meg Barbor, MPH

December 2019, Vol 10, No 6 - NCCN 2019 Hematologic Malignancies

San Francisco, CA—An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. He discussed this topic at the NCCN 2019 Hematologic Malignancies meeting. [ Read More ]

Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices

Meg Barbor, MPH

December 2019, Vol 10, No 6 - NCCN 2019 Hematologic Malignancies

San Francisco, CA—Keeping up with the many treatment advances in relapsed or refractory multiple myeloma can be a challenge for even the most informed providers, according to Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA. [ Read More ]